Radiotherapy combined with hormonal therapy in prostate cancer: The state of the art

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 243-253

  Milecki, Piotr ^a,b   Martenka, Piotr ^a   Antczak, Andrzej ^b   Kwias, Zbigniew ^b  

^a Great Poland Cancer Centre   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Androgen deprivation; Combined treatment; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GLUCOSE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; INSULIN; LEUPRORELIN; MEGESTROL ACETATE; PLACEBO; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ABDOMINAL OBESITY; ADJUVANT THERAPY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; BODY FAT; BONE DENSITY; BONE LESION; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER HORMONE THERAPY; CANCER MODEL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARPAL TUNNEL LIKE PAIN; CEREBROVASCULAR ACCIDENT; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; FRACTURE; GLUCOSE BLOOD LEVEL; HAND CHILL; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOGONADISM; IMPOTENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LEAN BODY WEIGHT; LIBIDO DISORDER; MENTAL DISEASE; METABOLIC DISORDER; METASTASIS INHIBITION; MICROMETASTASIS; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PAIN; PELVIS LYMPH NODE; PENIS ERECTION; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; SUDDEN DEATH; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 78049384849     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S8912     Document Type: Review

References (67)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238-244.
3. Widmark A, Klepp O, Kolberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): and open randomized phase III trial. Lancet. 2009;373: 301-308.
4. Milecki P, Kwias Z. Hormonal therapy combined with radiotherapy in locally advanced prostate cancer. Rep Pract Oncol Radiother. 2002;7:157-163.
5. Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev. 2009;35:540-546.
6. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95:981-989.
7. Shahinian VB, Kuo Y, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-1624.
8. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465-471.
9. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Rev Urol. 2007;9:163-180.
10. Huggins C, Hodges C. Studies on prostatic cancer: the effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1: 293-297.
11. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981-991.
12. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 2003;89:552-556.
13. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 2005;11:4653-4657.
14. Soloway M, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 1995;154:424-428.
15. Aus G, Abrahamsson PA, Ahlren G, et al. Hormonal treatment before radical prostatectomy: a 3-year follow-up. J Urol. 1998;159: 2016-2017.
16. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys. 1997;38: 1067-1070.
17. Mcconnell JD. Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am. 1991;18:1-7.
18. Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, Pollack A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys. 2003;57:24-28.
19. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997;49 Suppl 3 A:38-45.
20. Marcenaro M, Sanguineti G, Franzone P, et al. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51(ASTRO):18-19.
21. Movsas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology. 1999;53:11-18.
22. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl. 1992;13:457-464.
23. Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004;173:6098-6108.
24. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173-181.
25. ASTRO 2009, in November 2009 [ASTRO abstract]. RTOG 94-08.
26. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
27. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280-1283.
28. Ciezki JP, Klein EA, Angermeier K, et al. A retrospective comparison of androgen deprivation (AD) vs no AD among low-risk and intermediate- risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Biol Phys. 2004;60:1347-1350.
29. 2010 Genitourinary Cancers Symposium (GUCS) in San Francisco Abstract 6. 2010 Mar 5.
30. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827.
31. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cncer: a randomized trial. JAMA. 2008;299:289-295.
32. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841-850.
33. Radiation Theory Oncology Group. RTOG 99-10. A Phase III trial to evaluate the duration of neoadjuvant total androgen suppression (TAS) and radiation therapy (RT) in intermediate-risk prostate cancer. Available from http://www.rtog.org/members/protocols/99-10/99-10.pdf. Accessed 2010 September 27.
34. Radiation Theory Oncology Group. RTOG 08-15. A Phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate risk prostate cancer. Available from http://www.rtog.org/members/protocols/0815/0815.pdf. Accessed 2010 September 27.
35. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen supression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with def initive radiotherapy: report of Radiation Oncology Group Protocol 85-31. J Clin Oncol. 1997;15: 1013-1021.
36. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49: 937-946.
37. Miljenko V, Pilepich M, Winter K, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61: 1285-1290.
38. Pilepich MV, Winter K, Russell AH, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol. 1998;17:308a.
39. Miljenko V, Pilepich MV, Winter K, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50: 1243-1252.
40. Horwitz EM, Winter K, Hanks GE, et al. Subset analysis of RTOG 85-13 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer therapy with radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:947-956.
41. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
42. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combined therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Biol Phys. 1997;37: 247-252.
43. Hanks, Gerald E, Pajak K, et al. Phase III trial of longterm adjuvant adrogen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972-3978.
44. Tyrell CJ, Payne H, See WA, et al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localized or locally advanced prostate cancer: results from the randomized Early Prostate Cancer Programme. Radiother Oncol. 2005;76: 4-10.
45. Bolla M, de Reijke TM, Tienhoven GV, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360:2516-2527.
46. DiBlasio CJ, Malcolm JB, Derweesh IH, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int. 2008;102: 39-43.
47. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002;94:430-437.
48. Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer. 2002;95: 287-295.
49. Green HJ, Pakenham KI, Headley BC, et al. Quality of life compared during pharmacological treatments and clinical monitoring for nonlocalized prostate cancer: a randomized controlled trial. BJU Int. 2004;93:975-979.
50. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc. 2006; 54:85-90.
51. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and healthrelated quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology. 2002;11: 401-414.
52. Spetz AC, Hammar M, Lindberg B, Spangberg A, Varenhorst E; Scandinavian Prostatic Cancer Group-5 Trial Study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001;166:517-520.
53. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am. 2006;33: 181-190.
54. Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100:1060-1065.
55. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456.
56. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979-3983.
57. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581-588.
58. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91:1305-1308.
59. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
60. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007; 14:247-254.
61. Malcolm JB, Derweesh IH, Kincade MC, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol. 2007;14:3551-3559.
62. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352: 154-164.
63. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claimsbased cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897-7903.
64. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropinreleasing hormone agonists for prostatic carcinoma. J Urol. 1999;161: 1219-1222.
65. Malcolm JB, Diblasio CJ, Womack JH, et al. Association of cerebrovascular accident and myocardial infarction with Androgen Deprivation Therapy. J Urol. 2007;177:200.
66. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524.
67. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60;194-201.